NIMBLE | Non-Invasive Malignancy Classifiers Using Blood-Biomarkers for Lung Nodule Evaluation
Status: Recruiting
Location: See location...
Intervention Type: Diagnostic test
Study Type: Observational
SUMMARY
The goal of the NIMBLE study is to evaluate blood-based biomarkers for lung cancer risk prediction in patients referred with a lung nodule. Each blood biomarker will be evaluated for descriminating malignant from benign lung nodules alone and in combination with other blood biomarkers, patient characteristics and radiological features.
Eligibility
Participation Requirements
Sex: All
Healthy Volunteers: t
View:
• Patients with a newly detected IPN suspected of lung cancer referred to the infiltrate unit
• Having signed informed consent
Locations
Other Locations
Denmark
Gentofte Hospital
RECRUITING
Gentofte Municipality
Contact Information
Primary
Søren Egstrand, MD, PhD
soeren.egstrand@regionh.dk
0045 21682147
Time Frame
Start Date: 2024-05-22
Estimated Completion Date: 2028-02-01
Participants
Target number of participants: 1800
Treatments
Patients referred for work-up suspected of lung cancer
Patients are enrolled when these are referred to the Pulmonology Department suspected of lung cancer.
Related Therapeutic Areas
Sponsors
Collaborators: NEYE Foundation, Beckett Foundation, Toyota Foundation Denmark, Grosserer L. F. Foghts Fond Denmark, P. A. Messerschmidt & hustrus Fond, Direktør Michael Hermann Nielsens mindelegat, afd B
Leads: Herlev and Gentofte Hospital